MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• microRNA-218 (miR-218) is downregulated in non-small cell lung cancer (NSCLC).
• The role of miR-218 in cisplatin (DDP) chemosensitivity and its mechanism in NSCLC are not fully understood.

Purpose of the Study:

• To investigate if miR-218 influences NSCLC chemoresistance to cisplatin.
• To elucidate the molecular mechanism by which miR-218 affects chemoresistance.

Main Methods:

• Quantitative real-time polymerase chain reaction (qRT-PCR) for miR-218 expression.
• MTT assay for cell activity, flow cytometry for cell cycle and apoptosis.
• Luciferase reporter assays and Western blots to identify RUNX2 as a miR-218 target.

Main Results:

• miR-218 expression was significantly lower in cisplatin-resistant NSCLC cells (A549/DDP) compared to parent cells (A549).
• Increasing miR-218 levels enhanced NSCLC cell apoptosis and sensitivity to cisplatin.
• RUNX2 was confirmed as a direct target of miR-218, mediating chemoresistance.

Conclusions:

• Downregulation of miR-218 contributes to cisplatin chemoresistance in NSCLC by upregulating RUNX2.
• Targeting the miR-218/RUNX2 pathway presents a potential strategy to improve chemotherapy efficacy in NSCLC treatment.